Oncology Brothers: Practice-Changing Cancer Discussions

In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases.
The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics.
In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.
 
Key Points:
In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone.
Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off.
Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity.
Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression.
Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology!
#EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Isabel Preeshagul from Memorial Sloan-Kettering to discuss the latest advancements in lung cancer presented at ASCO 2026.
 
We dived into four key studies that could change clinical practice:
LIBRETTO-432: exploring the promising event-free survival data with selpercatinib in RET-positive disease and its implications for adjuvant therapy.
CROWN 7yr Update: seven-year progression-free survival results with lorlatinib in ALK-positive non-small cell lung cancer and the associated side effects.
CHRYSALIS-2: exciting findings regarding amivantamab for atypical EGFR mutations and its potential to become the new standard of care.
HARMONi-6: dual-headed drug ivonescimab combined with chemotherapy in metastatic squamous cell lung cancer and its intriguing results.
We also touched on the importance of molecular testing for all patients, regardless of stage or histology, and highlighted the latest updates on tarlatamab in small cell lung cancer.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Tune in for an insightful discussion that aims to keep our oncology community informed and engaged with the latest research and treatment options!
Don't forget to like, subscribe, and check out our other episodes for more insights on oncology treatments, conference highlights, and FDA approvals.
#ASCO2026, #LungCancer, #ALKPositive, #RETPositive, #OncologyBrothers

Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting.
 
We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively.
Topics Covered:
Overview of the RASolute-302 study
Impact of Daraxonrasib on overall survival
RAS mutations in pancreatic cancer
Mechanism of action of RAS inhibitors
Side effects and management strategies
Tune in now for an enlightening discussion on the future of pancreatic cancer treatment!
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
 
#ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Erika Hamilton from the Sarah Cannon Cancer Research Institute to discuss the latest advancements in breast cancer treatment following ESMO Breast 2026.
 
We dived into key studies and recent FDA approvals, including:
The exciting approval of Vepdegestrant from the VERITAC-2 study for ESR1-mutated breast cancer.
The importance of ovarian function suppression in premenopausal patients, even with the advent of oral SERDs.
Updates on HER2-positive disease treatments, including the newly approved T-DXd in neoadjuvant settings and the implications of de-escalation strategies.
Insights from the SATEEN and BRE-354 studies on the use of antibody-drug conjugates (ADCs) after previous ADC treatments.
A look at the Dato-DXd and Sacituzumab in frontline triple-negative breast cancer and how to choose between them.
Join us as we unpack these critical findings and their implications for clinical practice. Don't forget to check out our other episodes for more treatment algorithms and conference highlights.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Stay tuned for ASCO 2026, and remember, we are the Oncology Brothers!
#ESMO2026, #ESR1mutation, #BreastCancerResearch, #PrecisionMedicine, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of relapsed refractory acute myeloid leukemia (AML) with expert guest Dr. Joshua Zeidner, Chief of Leukemia Research at the University of North Carolina.
 
Join us as we explore two challenging cases:
Revumenib (menin inhibitor) demonstrated an overall response rate of ~63% in heavily pre-treated KMT2A rearrangement-positive AML patients based on the AUGMENT-101 study, with QTc prolongation and CYP3A4 drug interactions as key monitoring considerations.
FLT3 inhibitors like gilteritinib and quizartinib play an important role in MRD-positive FLT3 ITD/NPM1-mutated AML post-transplant, with the MORPHO trial supporting gilteritinib as maintenance therapy. 
Menin inhibitors may have a broader role in high-risk AML including NPM1-mutated disease, and re-evaluating mutational profiles at relapse is critical for optimal treatment selection. 
Careful monitoring of side effect profiles, drug interactions, and MRD status is essential when navigating targeted therapy decisions in relapsed refractory AML.
Throughout the episode, we discuss key practical points, including the importance of monitoring for QTc prolongation and the impact of drug interactions with CYP3A4 inhibitors.
Tune in for an informative discussion that sheds light on the latest advancements in targeted therapies for AML and the evolving landscape of treatment options.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and check out our other episodes in the challenging case series, treatment algorithms, and conference highlights!
#AcuteMyeloidLeukemia, #MeninInhibitor, #FLT3Inhibitor, #Hematology, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of chronic myeloid leukemia (CML) through two challenging case studies. Joined by CML experts Dr. Fadi Haddad from MD Anderson Cancer Center and Dr. Gaby Hobbs from Massachusetts General Hospital, 
 
we talked about:
The initial workup for diagnosing CML, including the importance of CBC, bone marrow biopsy, and BCR-ABL testing.
How to select the most optimal frontline treatment option amongst many available, considering factors like age, comorbidities, and the goal of treatment-free remission (TFR).
The role of first-generation TKI, but also how newer TKIs assist in achieving deeper molecular remissions.
Strategies for managing treatment breaks and monitoring patients in remission.
The role of ponatinib as a pan-BCR:ABL1 inhibitor effective against all known resistance mutations, including T315I, and the optimized response-based dosing strategy to balance efficacy with safety.
Tune in for valuable insights on treatment strategies, patient management, and the latest advancements in CML care. Don't forget to like, subscribe, and share your challenging case scenarios for future discussions!
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
#ChronicMyeloidLeukemia, #CML, #TreatmentFreeRemission, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafenib plus Binimetinib.
 
Key topics included:
Overview of the efficacy and survival data for both combinations
Side effect profiles and management strategies
Clinical pearls for oncologists in practice
The importance of NGS testing in smokers and the role of targeted therapy versus chemoimmunotherapy
Join us as we explore the latest insights and recommendations for managing these therapies, ensuring better patient outcomes and quality of life.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to check out our previous episodes for more on treatment algorithms and conference highlights!
#BRAFmutation, #NSCLC, #BRAF-MEK-inhibitor, #TargetedTherapy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of BRAF V600E-driven non-small cell lung cancer (NSCLC) with our guest Dr. Gregory Riely, a thoracic medical oncologist from Memorial Sloan Kettering Cancer Center.
 
Join us as we explore:
The prevalence of BRAF V600E mutations in NSCLC and how they compare to other oncogenic drivers.
The latest treatment options, including BRAF-MEK inhibitors like Encorafenib-Binimetinib and Dabrafenib-Trametinib.
Key clinical trial data that led to the approval of these therapies and their implications for patient care.
The role of immunotherapy in treating BRAF V600E patients and how to effectively sequence treatments.
Patient characteristics that influence treatment decisions, including smoking history and PD-L1 expression.
Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't miss it!
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
Subscribe to our channel for more discussions on oncology and stay updated on the latest in cancer care!
#BRAFV600E, #NSCLC, #BRAFMEKinhibitor, #TargetedTherapy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of bispecific antibodies approved for multiple myeloma. Joined by myeloma specialists Dr. Hamza Hashmi from Memorial Sloan Kettering and Dr. Cesar Rodriguez from Mount Sinai, they discussed the latest updates, clinical pearls, and practical insights for community oncologists.
 
Key topics included:
Overview of bispecific antibodies, focusing on GPRC5D and BCMA-targeted therapies.
Detailed discussion on talquetamab, teclistamab, elranatamab, and linvoseltamab, including dosing, side effects, and management strategies.
Insights on managing cytokine release syndrome (CRS), neurotoxicity, and other side effects like dysgeusia, skin toxicity, and infections.
Prophylactic measures, including the use of IVIG and tocilizumab, to enhance patient care and quality of life.
Whether you're a healthcare professional or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and check out our other episodes for more insights into oncology!
#MultipleMyeloma, #BispecificAntibody, #ICANS, #CRSmanagement, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the world of anti-EGFR therapies in non-small cell lung cancer (NSCLC). Joined by Dr. Joshua Sabari from NYU Langone Health and Dr. Azam Farooqui from Ironwood Cancer and Research Center, we discussed the latest advancements in treatment options, including the use of osimertinib, afatinib, and the combination therapy of amivantamab and lazertinib.
 
Key topics include:
The role of afatinib in treating uncommon EGFR mutations and its associated toxicities
The well-tolerated profile of osimertinib and its common side effects, including rash, diarrhea, and the rare risk of pneumonitis
Insights into the combination therapy of amivantamab and lazertinib, including management of skin toxicity and the importance of prophylactic anticoagulation to mitigate VTE risks
The episode emphasized the importance of maintaining quality of life for patients while ensuring they can stay on effective therapies for longer periods. Tune in for valuable clinical pearls and strategies to optimize patient care in the community setting.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don’t forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms and conference highlights!
#LungCancer, #NSCLC, #EGFR, #TargetedTherapy, #OncologyBrothers